NCT01200485 2020-01-31
Rasburicase in Patients at High Risk for Tumor Lysis Syndrome (TLS) During Cycle-2
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
6 trialsNCT00186940 2017-04-25
Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients
St. Jude Children's Research Hospital
Completed
NCT00628628 2013-08-01
Rasburicase in Patients at Risk for Tumor Lysis Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00360438 2012-08-01
Pharmacokinetic Evaluation of Rasburicase in Patients With Leukemia and/or Lymphoma at High Risk of TLS
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00230178 2010-01-12
Rasburicase Versus Allopurinol in Tumor Patients at Risk for Hyperuricemia and Tumor Lysis Syndrome
Sanofi
Phase 3 Completed
NCT00230217 2009-03-30
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
Sanofi
Phase 4 Completed